Company news
Nuvalent, Inc. news in 2022
Nuvalent, Inc.'s news releases, calls and decks from 2022, newest first.
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
December 12, 2022
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
November 9, 2022
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC
October 27, 2022
Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655
October 25, 2022
Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium
October 16, 2022
Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors
October 5, 2022
Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates
September 6, 2022
Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference
August 31, 2022
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
August 9, 2022
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
August 4, 2022
Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 2, 2022
Nuvalent Announces Leadership Promotions
July 19, 2022
Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
July 12, 2022
Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
June 20, 2022
Nuvalent to Present at the 2022 Jefferies Healthcare Conference
June 1, 2022
Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results
May 11, 2022
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
April 7, 2022
Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference
April 6, 2022
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
March 30, 2022
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
March 7, 2022
Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference
March 1, 2022
Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors
February 2, 2022
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
January 6, 2022
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022